Live feed07:00:00·443dPRReleasevia QuantisnowRhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic ObesityByQuantisnow·Wall Street's wire, on your screen.RYTM· Rhythm Pharmaceuticals Inc.Health Care
